Erasca

Erasca, Inc. was founded in 2018 as a biotechnology company focused on eradicating cancer. The company's proprietary artificial intelligence drug discovery platform, OPRA, leverages advanced computational tools such as machine learning to accelerate drug discovery by elucidating novel tumor biology and innovative strategies to shut down cancer pathways (via both single-agent and combination approaches targeting key cancer pathways). OPRA currently encompasses Erasca’s established drug discovery processes, enabling Erasca scientists to focus their research on the most promising strategies, thereby expediting the progression of drug candidates into clinical trials. Currently, Erasca is advancing multiple undisclosed-target R&D programs aimed at drivers of cancer biology. The company stated that more project-related information will be disclosed as these programs enter human clinical studies. Additionally, according to its official website, besides programs targeting undisclosed cancer targets, the company also plans to expand into areas such as metabolism and genomics to develop innovative therapies for various solid tumors.